- Conditions
- Eczema, Atopic Dermatitis
- Interventions
- Not listed
- Lead sponsor
- TopMD Skin Care, Inc.
- Industry
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 482
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- BIBF 1120, Phone Call
- Drug · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- docetaxel, protein expression analysis, laboratory biomarker analysis, biopsy, conventional surgery, neoadjuvant therapy
- Drug · Genetic · Other + 1 more
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee
- Conditions
- HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Breast Adenocarcinoma, Inflammatory Breast Carcinoma
- Interventions
- pertuzumab, trastuzumab, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 3
- States / cities
- Duarte, California • Lancaster, California • South Pasadena, California
- Conditions
- Moderate to Severe Plaque-type Psoriasis
- Interventions
- AIN457 150mg, AIN457 300mg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 967 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 33
- States / cities
- Fresno, California • Pasadena, California • Sacramento, California + 28 more
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
- Interventions
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 0 Years to 20 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- AIN457, Placebo, Abatacept
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 551 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 44
- States / cities
- Anniston, Alabama • Vestavia Hills, Alabama • Freemont, California + 40 more
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma, Breast Inflammatory Carcinoma, Locally Recurrent Breast Carcinoma
- Interventions
- Exercise Intervention, Educational Intervention, Supportive Care, Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration, Accelerometry, Electronic Health Record Review, Cardiopulmonary Exercise Testing
- Other · Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Winston-Salem, North Carolina • Richmond, Virginia
- Conditions
- Stroke, Acute
- Interventions
- Minocycline
- Drug
- Lead sponsor
- David Hess, MD
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- Lexington, Kentucky • Portland, Oregon
- Conditions
- Psoriasis, Plaque Psoriasis
- Interventions
- Halobetasol Propionate Lotion 0.05%, Placebo
- Drug
- Lead sponsor
- Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 3
- States / cities
- San Diego, California • Fridley, Minnesota • Austin, Texas
- Conditions
- Intestinal Disorders, Bowel Diseases, Inflammatory
- Interventions
- TD-1473 oral capsule, [14C]-TD-1473 IV bolus, [14C]-TD-1473 Oral Capsule
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 19 Years to 55 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Post-inflammatory Hyperpigmentation
- Interventions
- Tricholoacetic Acid (TCA)
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Complicated Skin and Soft Tissue Infection
- Interventions
- Ceftaroline fosamil, Vancomycin, Aztreonam
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 802 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 10
- States / cities
- Chula Vista, California • Orlando, Florida • West Palm Beach, Florida + 7 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 504 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 24 more
- Conditions
- Acne Vulgaris, Post Inflammatory Hyperpigmentation, Post Inflammatory Pigmentation Change, Erythema, Skin Scarring
- Interventions
- Tazarotene 0.045% Lotion
- Drug
- Lead sponsor
- Dr. Emmy Graber
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- capecitabine, paclitaxel albumin-stabilized nanoparticle formulation, neoadjuvant therapy
- Drug · Procedure
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Respiratory Tract Infections, Urinary Tract Infections, Skin and Soft Tissue Infections, Intraabdominal Infections, Sepsis
- Interventions
- HostDx Sepsis
- Diagnostic Test
- Lead sponsor
- Inflammatix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 585 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Lexington, Kentucky • Springfield, Massachusetts + 3 more
- Conditions
- SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis
- Interventions
- CTX112
- Biological
- Lead sponsor
- CRISPR Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 9
- States / cities
- La Jolla, California • Redwood City, California • Chicago, Illinois + 6 more
- Conditions
- Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Rheumatoid Arthritis (RA), Crohn's Disease (CD), Psoriatic Arthritis (PsA), Axial Spondyloarthritis and Ankylosing Spondylitis
- Interventions
- Not listed
- Lead sponsor
- UCB BIOSCIENCES, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
- Conditions
- Acne Vulgaris
- Interventions
- Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel, Oral doxycycline hyclate
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Rheumatoid Arthritis
- Interventions
- Upadacitinib, Pneumococcal 13-valent conjugate vaccine (PCV-13)
- Drug · Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 52
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Hemet, California + 44 more
- Conditions
- Crohn's Disease, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis
- Interventions
- Not listed
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- Female only
- Enrollment
- 925 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Arthritis, Rheumatoid, Arthritis, Psoriatic, Ankylosing Spondylitis
- Interventions
- tgAAC94 gene therapy vector, tgAAC94 placebo
- Genetic
- Lead sponsor
- Targeted Genetics Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 22
- States / cities
- Glendale, Arizona • Tuscon, Arizona • Palm Desert, California + 18 more